Current Report Filing (8-k)
29 March 2017 - 12:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2017
CEMPRA, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35405
|
|
45-4440364
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
ID Number)
|
|
|
|
|
|
6320 Quadrangle Drive, Suite 360, Chapel Hill, NC
|
|
27517
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (919)
313-6601
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
On March 28, 2017, we issued a press release to report that we have
withdrawn our marketing authorization application seeking European Medicines Agency approval in Europe of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired pneumonia in adults, with plans to resubmit
the application with additional data in alignment with our FDA strategy.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release dated March 28, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
CEMPRA, INC.
|
|
|
|
|
Date: March 28, 2017
|
|
|
|
|
|
/s/ Mark W. Hahn
|
|
|
|
|
|
|
Mark W. Hahn, Chief Financial Officer
|
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Apr 2024 to May 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Cempra (NASDAQ): 0 recent articles
More Cempra, Inc. News Articles